Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - azilsartanum medoxomilum, chlortalidonum - compresse rivestite con film - azilsartanum medoxomilum 40 mg ut azilsartanum medoxomilum kalicum, chlortalidonum 12.5 mg, mannitolum, cellulosum microcristallinum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, crospovidonum, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), pro compresso obducto corresp. natrium 0.4 mg. - ipertensione - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - azilsartanum medoxomilum, chlortalidonum - compresse rivestite con film - azilsartanum medoxomilum 40 mg ut azilsartanum medoxomilum kalicum, chlortalidonum 25 mg, mannitolum, cellulosum microcristallinum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, crospovidonum, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), pro compresso obducto corresp. natrium 0.4 mg. - ipertensione - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - teduglutidum - polvere e solvente per soluzione iniettabile - praeparatio cryodesiccata: teduglutidum 5 mg, histidinum, mannitolum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii hydroxidum, acidum hydrochloridum, pro vitro corresp. natrium 0.7 mg. solvens: aqua ad iniectabile 0.5 ml, pro vitro. - per il trattamento di pazienti con sindrome dell'intestino corto dall'età di 1 anno, che dipendono dalla nutrizione parenterale - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - mesalazinum - 1,2 g gastroresistenti a rilascio prolungato - mesalazinum 1.2 g, carmellosum natricum, cera carnauba, acidum stearicum, silica colloidalis hydrica, carboxymethylamylum natricum a, talcum, magnesii stearas, Überzug: talcum, acidi methacrylici copolymerum a, acidi methacrylici copolymerum b, triethylis citras, macrogolum 6000, e 171, e 172 (rubrum) pro compresso obducto corresp. natrium 5.66 mg. - la colite ulcerosa - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 1 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.03570261 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 23.59 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 2 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.071402 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 47.18 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 3 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.04073661 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 39.80 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 4 mg ut guanfacini hydrochloridum 4.56 mg, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.054581 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 53.07 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - vedolizumabum - injektionslösung in einem fertigpen - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - colite ulcerosa, morbo di crohn - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - vedolizumabum - injektionslösung in einer fertigspritze - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - colite ulcerosa, morbo di crohn - biotechnologika